Cancers (Mar 2022)

High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary Adenocarcinoma

  • Arik Bernard Schulze,
  • Anna Kuntze,
  • Lars Henning Schmidt,
  • Michael Mohr,
  • Alessandro Marra,
  • Ludger Hillejan,
  • Christian Schulz,
  • Dennis Görlich,
  • Wolfgang Hartmann,
  • Annalen Bleckmann,
  • Georg Evers

DOI
https://doi.org/10.3390/cancers14061395
Journal volume & issue
Vol. 14, no. 6
p. 1395

Abstract

Read online

Via immunohistochemistry (IHC) on tissue micro arrays (TMA) clinical and prognostic impact of p53 co-playing 5′-Nucleotidase Domain-Containing Protein 2 (NT5DC2) protein expression was evaluated in 252 NSCLC patients. Confirmatory, gene expression database. mRNA levels of NT5DC2 were studied in 1925 NSCLC patients. High protein expression of NT5DC2 resulted in reduced median overall survival (OS) of patients with stage I-III adenocarcinoma (ADC) (Log Rank p = 0.026, HR 2.04 (1.08–3.87)), but not in squamous cell carcinoma (SCC) (p = 0.514, HR 0.87 (0.57–1.33)). Findings on OS were reproduced via gene expression analysis in ADC (p p = 0.217, HR 0.86 (0.68–1.09)). Yet, NT5DC2 mRNA levels were higher in SCC compared to ADC (p p = 0.001). Likewise, NT5DC2 protein expression associated with high-grade SCC. Moreover, NT5DC2 expression was positively correlated with p53 protein (p = 0.018) and TP53 gene expression (p p = 0.065).

Keywords